Clinical development of virotherapy for cancer with telomelysin

Toshiyoshi Fujiwara, Noriaki Tanaka, Yasuo Urata

Research output: Contribution to journalArticlepeer-review


The major cause of death in Japan has evolved from infectious diseases to aging and lifestyle-related causes, with cancer now the leading cause of death. Although the survival rate five years after cancer detection has been increasing due to novel anti-tumor drugs and chemotherapy combinations, side effects such as blood disorders, hair loss, nausea, neuropathy, and other complications still accompany the disease. Antibodies and molecular-targeted medicine have proved to be effective and safe for specific types of cancers, however, the whole world is waiting for more potent, safe, and innovative anticancer agents. Oncolys BioPharma, Inc. is a biopharmaceutical bioventure company focused on the discovery, development and commercialization of viral products for the treatment of cancer. Oncolys has established product-driven collaborative arrangements with Okayama University. Telomelysin is a replication-competent oncolytic adenovirus designed in Okayama University. When injected directly to solid tumors, Telomelysin infects tumor cells and replicates consequently, causing tumor cell death and demonstrating clear therapeutic benefits. Oncolys BioPharma believes that through the development of the replication-competent oncolytic virus, we produce safer, more effective, QOL-improving approaches which will revolutionize the current mode of cancer therapy.

Original languageEnglish
Pages (from-to)310-317
Number of pages8
Issue number3
Publication statusPublished - May 2006


  • Adenovirus
  • Bioventure
  • Virotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Clinical development of virotherapy for cancer with telomelysin'. Together they form a unique fingerprint.

Cite this